Animal models of hemophilia
- PMID: 22137432
- PMCID: PMC3713797
- DOI: 10.1016/B978-0-12-394596-9.00006-8
Animal models of hemophilia
Abstract
The X-linked bleeding disorder hemophilia is caused by mutations in coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Unless prophylactic treatment is provided, patients with severe disease (less than 1% clotting activity) typically experience frequent spontaneous bleeds. Current treatment is largely based on intravenous infusion of recombinant or plasma-derived coagulation factor concentrate. More effective factor products are being developed. Moreover, gene therapies for sustained correction of hemophilia are showing much promise in preclinical studies and in clinical trials. These advances in molecular medicine heavily depend on availability of well-characterized small and large animal models of hemophilia, primarily hemophilia mice and dogs. Experiments in these animals represent important early and intermediate steps of translational research aimed at development of better and safer treatments for hemophilia, such a protein and gene therapies or immune tolerance protocols. While murine models are excellent for studies of large groups of animals using genetically defined strains, canine models are important for testing scale-up and for long-term follow-up as well as for studies that require larger blood volumes.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.CMAJ. 1995 Jul 15;153(2):147-57. CMAJ. 1995. PMID: 7600466 Free PMC article.
-
Gene transfer as an approach to treating hemophilia.Circ Res. 2001 Feb 2;88(2):137-44. doi: 10.1161/01.res.88.2.137. Circ Res. 2001. PMID: 11157664 Review.
-
Advances toward gene therapy for hemophilia at the millennium.Hum Gene Ther. 1999 Sep 1;10(13):2091-107. doi: 10.1089/10430349950017095. Hum Gene Ther. 1999. PMID: 10498242 Review.
-
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.ILAR J. 2009;50(2):144-67. doi: 10.1093/ilar.50.2.144. ILAR J. 2009. PMID: 19293459 Free PMC article. Review.
-
Recent progress in gene therapy for hemophilia.Hum Gene Ther. 2012 Jun;23(6):557-65. doi: 10.1089/hum.2012.088. Hum Gene Ther. 2012. PMID: 22671033 Review.
Cited by
-
Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants.Blood Adv. 2021 Mar 9;5(5):1324-1332. doi: 10.1182/bloodadvances.2019000405. Blood Adv. 2021. PMID: 33656538 Free PMC article.
-
IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia.J Thromb Haemost. 2013 May;11(5):881-93. doi: 10.1111/jth.12176. J Thromb Haemost. 2013. PMID: 23413986 Free PMC article.
-
Initial joint bleed volume in a delayed on-demand treatment setup correlates with subsequent synovial changes in hemophilic mice.Animal Model Exp Med. 2020 Jun 3;3(2):160-168. doi: 10.1002/ame2.12118. eCollection 2020 Jun. Animal Model Exp Med. 2020. PMID: 32613175 Free PMC article.
-
Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A.Hum Gene Ther. 2022 Apr;33(7-8):421-431. doi: 10.1089/hum.2021.108. Epub 2021 Dec 8. Hum Gene Ther. 2022. PMID: 34652966 Free PMC article.
-
In vitro and In vivo Model Systems for Hemophilia A Gene Therapy.J Genet Syndr Gene Ther. 2013 Jan 17;Suppl 1:10911. doi: 10.4172/2157-7412.S1-014. J Genet Syndr Gene Ther. 2013. PMID: 25401041 Free PMC article.
References
-
- Antonarakis SE, Kazazian HH, Gitschier J, Hutter P, de Moerloose P, Morris MA. Molecular etiology of factor VIII deficiency in hemophilia A. Adv Exp Med Biol. 1995;386:19–34. - PubMed
-
- Elder B, Lakich D, Gitschier J. Sequence of the murine factor VIII cDNA. Genomics. 1993;16:374–379. - PubMed
-
- Brinkhous KM, Graham JB. Hemophilia in the female dog. Science. 1950;111:723–724. - PubMed
-
- Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature. 1984;312:326–330. - PubMed
-
- Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH., Jr Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10:119–121. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical